Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

T cell mediated immunotherapy for B cell lymphoma.

J L Schultze1, L M Nadler

  • 1Department of Adult Oncology, Disease Center for Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA. schultze@mbcrr.harvard.edu

Journal of Molecular Medicine (Berlin, Germany)
|March 25, 1999
PubMed
Summary

Chemotherapy often fails for B cell non-Hodgkin's lymphoma (NHL). Immunotherapy, particularly T cell-based strategies targeting tumor antigens, offers promising new treatment avenues for NHL patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Apolipoprotein E controls Dectin-1-dependent development of monocyte-derived alveolar macrophages upon pulmonary β-glucan-induced inflammatory adaptation.

Nature immunology·2024
Same author

A cross-species approach to identify transcriptional regulators exemplified for Dnajc22 and Hnf4a.

Scientific reports·2017
Same author

Chromatin Remodeling in Monocyte and Macrophage Activation.

Advances in protein chemistry and structural biology·2017
Same author

CD11b(+)Ly6C(++)Ly6G(-) Cells with Suppressive Activity Towards T Cells Accumulate in Lungs of Influenza a Virus-Infected Mice.

European journal of microbiology & immunology·2015
Same author

Alloanergization of human T cells results in expansion of alloantigen-specific CD8(+) CD28(-) suppressor cells.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2014
Same author

FOXP3 and FOXP3-regulated microRNAs suppress SATB1 in breast cancer cells.

Oncogene·2011

Area of Science:

  • Oncology
  • Immunology
  • Hematology

Background:

  • Chemotherapy demonstrates limited efficacy in curing most B cell non-Hodgkin's lymphoma (NHL) cases.
  • Novel therapeutic approaches are essential for improving patient outcomes in NHL.
  • Immunotherapy has emerged as a viable alternative treatment strategy.

Purpose of the Study:

  • To review current and emerging immunotherapeutic strategies for B cell non-Hodgkin's lymphoma.
  • To explore the potential of T cell-mediated immunity in treating B cell lymphomas.
  • To discuss the use of tumor-specific antigens in novel lymphoma treatments.

Main Methods:

  • Review of existing literature on immunotherapy for B cell lymphomas.
  • Discussion of monoclonal antibody-based therapies.

Related Experiment Videos

  • Exploration of T cell-based immunotherapeutic approaches utilizing tumor-specific antigens.

    • Main Results:

    • Monoclonal antibody immunotherapy has shown efficacy in preclinical models and human patients.
    • T cell-mediated immunity is being revitalized for B cell lymphoma treatment.
    • Lymphoma-specific idiotype and modified malignant B cells serve as potential tumor antigens.

    Conclusions:

    • Immunotherapy represents a promising frontier for B cell non-Hodgkin's lymphoma treatment.
    • Targeting tumor-specific antigens with T cells offers a new paradigm for lymphoma therapy.
    • Further research into these immunotherapeutic strategies is warranted to improve NHL management.